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Abstract
Background: We used a PCR-based approach to study the prevalence of genetic sequences related to a
gammaretrovirus, xenotropic murine leukemia virus-related virus, XMRV, in human prostate cancer. This virus has
been identified in the US in prostate cancer patients and in those with chronic fatigue syndrome. However, with
the exception of two patients in Germany, XMRV has not been identified in prostate cancer tissue in Europe. Most
putative associations of new or old human retroviruses with diseases have turned out to be due to contamination.
We have looked for XMRV sequences in DNA extracted from formalin-fixed paraffin- embedded prostate tissues. To
control for contamination, PCR assays to detect either mouse mitochondrial DNA (mtDNA) or intracisternal A
particle (IAP) long terminal repeat DNA were run on all samples, owing to their very high copy number in mouse
cells.
Results: In general agreement with the US prevalence, XMRV-like sequences were found in 4.8% of prostate
cancers. However, these were also positive, as were 21.5% of XMRV-negative cases, for IAP sequences, and many,
but not all were positive for mtDNA sequences.
Conclusions: These results show that contamination with mouse DNA is widespread and detectable by the highly
sensitive IAP assay, but not always with less sensitive assays, such as murine mtDNA PCR. This study highlights the
ubiquitous presence of mouse DNA in laboratory specimens and offers a means of rigorous validation for future
studies of murine retroviruses in human disease.
Background
In 2006, XMRV was identified in stromal cells asso-
ciated with prostate cancers of men with a family his-
tory of the malignancy, 40% of whom were homozygous
for a specific variant of the interferon-inducible RNaseL
gene, suggesting an increased susceptibility to viral
infection in these patients. Virochip microarray analysis
on cDNA from some of these tumours led to the identi-
fication of XMRV [1], a gammaretrovirus closely related,
but not identical, to endogenous MLV. Interest in
XMRV intensified when 6% of all prostate cancers in a
US clinic were found to carry the virus and when by
immuno-histochemical staining the virus was detected
in the tumour epithelium of 23% of those patients. In
the latter study, virus detection was associated with a
higher Gleason Index and appeared to be independent
of the RNAseL mutation [2]. Several papers have since
demonstrated a link of prostate cancer with XMRV
[3-5], however this has not been repeated in other
cohorts [6-9].
XMRV has also been reported in patients suffering
from chronic fatigue syndrome (CFS) [10], a condition
also associated with perturbations in the RNaseL innate
defence response. In addition, XMRV has been
described in the bronchiolar lavages of immunosup-
pressed individuals [11]. Several groups have presented
unambiguous data challenging the original findings,
both in European CFS cohorts [12-14] and in US CFS
patients [15,16]. More recently, matters were further
complicated by the publication of a study finding gag
sequences similar to those of four different polytropic
endogenous MLVs in an unrelated US CFS cohort, but
no evidence of XMRV [17]. A clear account of the
* Correspondence: m.mcclure@imperial.ac.uk
† Contributed equally
1Section of Infectious Diseases, Jefferiss Research Trust Laboratories, Imperial
College London, St Mary’s Campus, London, W2 1PG, UK
Full list of author information is available at the end of the article
Robinson et al. Retrovirology 2010, 7:108
http://www.retrovirology.com/content/7/1/108
© 2010 Robinson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.claims and counter-claims surrounding XMRV and its
disease association has recently been published [18].
Methods
The UK prostate specimens in this study came from two
sources. Cancer tissue came from men locally referred
to St Mary’s Hospital in West London with symptoms
of voiding dysfunction and prostate specific antigen
abnormality and requiring biopsy after appropriate
counselling. In addition, some patients had participated
in a voluntary screening study and these provided sam-
ples that were a mixture of benign and cancer patholo-
gies. All biopsy tissue had been stored in formalin fixed,
paraffin-embedded (FFPE) blocks over a period of 3-6
years. Slices were taken from the blocks and DNA
extracted as described (see Additional File 1; Supple-
mentary Methods). The FFPE samples from Thailand
and Korea were excess tissue from histological samples
taken from new cases of both benign prostate hyperpla-
sia and prostate cancer. These were FFPE embedded
and sent to London for analysis.
We investigated the prevalence of XMRV in the UK
and in the Far East, aware that the close relationship
(about 94% at the nucleotide level) to other murine exo-
genous and endogenous retroviruses posed a problem in
distinguishing XMRV from contaminating mouse DNA
sequences. We were further aware that in any retrovirol-
ogy laboratory MLV sequence contamination is some-
thing of an occupational hazard [19]. For these reasons,
we extracted the DNA from FFPE prostate cancers,
along with benign hyperplasia tissue, and PBS without
tissue. We used several sets of primers [12] to test for
XMRV-specific sequences, derived from the XMRV gag
leader [1] which encompasses the 24 bp deletion origin-
ally thought to distinguish XMRV as a new human
virus. To control for low level contamination, we
included multiple no-template controls (no less than 6
in every run) and included assays with primers that
would amplify murine mitochondrial DNA (mtDNA)
and intracisternal A particle (IAP) LTRs. IAPs are retro-
transposons present at the level of about 1000 copies of
varying length per mouse genome [20].
Results
All murine retroviral primer sequences amplified speci-
fic products of the appropriate size when tested on
pXMRV isolate VP62, an infectious molecular clone of
XMRV, kindly provided by R. Silverman. The IAP pri-
mers did not amplify sequences from human DNA
extracted from LNCaP cells (prostate cancer cell line) or
from six PBMC samples from human prostate cancer
patients (data not shown).
FFPE prostate tumour slices (two 10 micron slices
from each lobe of the prostate) were provided to us
blinded by the Histopathology Department at St Mary’s
Hospital in batches and randomised with benign pros-
tate hyperplasia specimens. For samples received from
Thailand and Korea, those carrying out the PCR were
blinded to sample provenance. In all cases, care was
t a k e nt ou s eaf r e s hb l a d ef o rs l i c i n ge a c hp a t i e n ts a m -
ple, and the top slice was discarded. In total, of 292 UK
prostate cancers analysed, 14 were XMRV-positive by
PCR using the gag leader primers, as were five out of
139 Korean samples and two out of six from Thailand.
A representative result is shown in Figure 1.
All FFPE prostate cancer specimens from the Pathol-
ogy Department at St Mary’s hospital London were pro-
vided to us in batches. The tissue slices were coded and
assayed blind. Initially, the PCR amplification and
sequence analysis of the amplicons encouraged us to
deduce that we had detected a genuine XMRV infection
in some of the samples. When on unblinding we found
a concordant result from the same patient whose dupli-
cate specimens had been provided in different batches,
this appeared to reaffirm a genuine XMRV infection.
Moreover, in two patients in whom the tumour was uni-
lateral, XMRV was detected only in the cancerous lobe.
Taken together with the consistently negative PCR
water controls, the probability of contamination
appeared to be low.
Upon sequencing, however, we noticed differences in
the obtained PCR products. Some sequences displayed
the deletion characteristic of XMRV upstream of the gag
ATG (Korean samples 12, 35, 15), and UK (sample 244),
while others did not (Thai patients 1 and 2 and Korean
16) (Figure 2). Downstream of this deletion all sequences
are identical, apart from an A > G mutation at position
647, but there is no correlation of the A647G mutation
with the presence of the deletion. Sequences that did
not contain the deletion were amplified, indicating that
the primers were not as specific to XMRV as expected.
A BLAST search showed the best match for sequences
without the deletion but containing a G at position 647
to be mouse endogenous polytropic provirus clone 15
[Genbank:FJ544577.1], which suggests the presence of
mouse DNA in these samples. It has been shown
recently that the 24 bp deletion specific to XMRV [1], is
also present in the sequence of a polytropic endogenous
MLV sequence [Genbank:AAHY01591888.1] in the
laboratory mouse strain 129X1/SvJ, commonly used
in gene knock-out experiments [21]. Our sequences
(Korean samples 12, 35, 15; and UK sample 244) are
identical to this PMLV sequence present in strain
129X1/SvJ (Figure 2). We therefore, sought to investi-
gate this potential contamination further.
The IAP and mtDNA PCR assays were applied to
10-fold dilution series of McCoy cell and RAW 264.7
cell DNA to compare the sensitivity of the methods for
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Figure 1 Nested PCR on DNA extracted from FFPE tissue of prostate cancer patients. Figure (a) shows samples that produced a PCR
product of the expected size using primers specific for XMRV (lanes 1-5). UK patient 308 and UK 244 (Lane 1 and 2); Thailand 1 and Thailand 2
(Lane 3 and Lane 4); Korea 62 (Lane 5). Lanes 6-8 show samples in which XMRV was not detected. Thailand 3 (Lane 6); Korea 60 (Lane 7); Korea
61(Lane 8); Positive control pXMRV produces a strong band (lane 9). Promega 200 bp DNA step ladder (lane 10). Lanes 11-13 show water
negative controls. Figure (b) shows b-globin control PCR used to demonstrate the presence of human DNA in each sample (lanes 1-8, as above).
Expected size was 104 bp. Positive control LNCaP DNA is shown in lane 9. Lanes 11-13 show negative water controls. All patient samples tested
showed a positive signal for b-globin. Figure (c) shows the IAP PCR result for the same samples (lanes 1-5 IAP positive, lanes 6-8 IAP negative).
Positive control McCoy cell DNA is shown in lane 9. Invitrogen 100 bp DNA step ladder (lane 10). Lanes 11-13 show negative water controls.
Figure (d) shows the mtDNA PCR results for the same sample (lane 1 mtDNA positive, lanes 2-8 mtDNA negative) Positive control McCoy cell
DNA is shown in lane 9. Invitrogen 100 bp DNA step ladder (lane 10). Lanes 11-13 show negative water controls.
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mtDNA PCR (14) 100-fold less sensitive than that for
IAP in both cell lines (see Additional File 2; Figure S1).
The IAP PCR, thus, provided a far more reliable indica-
tor of contaminating murine sequences. The IAP and
mtDNA PCR assays were applied to the same sample to
test whether the apparent XMRV positivity might have
been due to mouse DNA contamination. Amplification
of XMRV-specific sequences was completely concordant
with amplification of IAP sequences from the same
DNA (Table 1). Samples from 292 UK patients, of
which 212 (73%) were cancerous, 68 (23%) were benign
and 12 (4%) were lost to follow up, along with 139
Korean samples (all cancerous) and 6 Thai samples
(50% cancerous, 50% benign) were tested by XMRV,
IAP and mtDNA by PCR. Twenty-one samples were
positive for XMRV using the gag leader primers, and of
these, 17 were from cancerous tissue and 4 from benign
tissue. Overall, 115/437 (26.3%) of the samples, includ-
ing all 21 of the XMRV-positives were positive for IAP
sequences and 21/115 (18.2%), of the IAP positives con-
tained mouse mtDNA. To confirm that the sequences
amplified by the IAP primers were indeed murine in ori-
gin, we cloned and sequenced one of the amplicons.
Several IAP sequences were obtained (see Additional
File 3; Figure S2). The fact that not all IAP positives
were XMRV positive may be explained by the low level
of contamination of murine DNA that would contain
only a few copies of endogenous XMRV like sequences
compared to the many IAP copies per genome.
Discussion
XMRV shares extensive sequence identity with known
xenotropic, nonecotropic and polytropic murine viruses;
the first of which is known to infect many common
human tumour cell lines, a phenomenon that has con-
fused retrovirologists looking for disease associations for
over three decades. Most putative associations of new or
old human retroviruses with diseases (including CFS
and prostate cancer) have turned out to be laboratory
artefacts [19]. The case of XMRV as a new human
pathogen must be judged against this background [22].
                       ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
                               510        520        530        540        550        560        570        580        590    600
CFS-TYPE1    ---------- ---------- --ATCAGTTA ACCTACCCGA GTCGGACTTT TTGGAGCTCC GCCACTGTAC GTGGCTTTGT TGGGGGACGA GAGACAGAGA 
VP_62    CCCGTTTTGT GGCCCATTCT GTATCAGTTA ACCTACCCGA GTCGGACTTT TTGGAG---- ---------- -TGGCTTTGT TGGGGGACGA GAGACAGAGA 
129X1/Sv strain mouse  CCCGTTTTGT GGCCCATTCT GTATCAGTTA ACCTACCCGA GTCGGACTTT TTGGAG---- ---------- -TGGCTTTGT TGGGGGACGA GAGACAGAGA 
Korea 12 clone 1    ---------- ---------- ---------- ------CCGA GTCGGACTTT TTGGAG---- ---------- -TGGCTTTGT TGGGGGACGA GAGACAGAGA 
Korea 35 clone 5    ---------- ---------- ---------- ------CCGA GTCGGACTTT TTGGAG---- ---------- -TGGCTTTGT TGGGGGACGA GAGACAGAGA 
Korea 35 clone 15    ---------- ---------- ---------- ------CCGA GTCGGACTTT TTGGAG---- ---------- -TGGCTTTGT TGGGGGACGA GAGACAGAGA 
Korea 15 clone 1    ---------- ---------- ---------- ------CCGA GTCGGACTTT TTGGAG---- ---------- -TGGCTTTGT TGGGGGACGA GAGACAGAGA 
UK 244 clone 1    ---------- ---------- ---------- ------CCGA GTCGGACTTT TTGGAG---- ---------- -TGGCTTTGT TGGGGGACGA GAGACAGAGA 
Thailand 1 clone_1    ---------- ---------- ---------- ---------- ---------- -TGGAGCTCC GCCACTGTAC GTGGCTTTGT TGGGGGACGA GAGACAGAGA 
Thailand 2 clone 1    ---------- ---------- ---------- ---------- ---------- -TGGAGCTCC GCCACTGTAC GTGGCTTTGT TGGGGGACGA GAGACAGAGA 
Korea 16 clone_1    ---------- ---------- ---------- ---------- ---------- -TGGAGCTCC GCCACTGTAC GTGGCTTTGT TGGGGGACGA GAGACAGAGA 
Korea 16 clone 2    ---------- ---------- ---------- ---------- ---------- -TGGAGCTCC GCCACTGTAC GTGGCTTTGT TGGGGGACGA GAGACAGAGA 
Thailand 2 clone 3    ---------- ---------- ---------- ---------- ---------- -TGGAGCTCC GCCACTGTAC GTGGCTTTGT TGGGGGACGA GAGACAGAGA
XMRV-F-O                                TTCT GTATCAGTTA ACCTAC
J
                       ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
                               610        620        630        640        650        660        670        680        690    700
CFS-TYPE1    CACTTCCCGC CCCCGTCTGG ATTTTTGCTT TCGGTTTTAC GCCGAAACCG CGCTGCGCGT CTGATTTGTT TTATTGCTCT TTTGTTCTTC GTTAGTTTTT 
VP_62    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAACCG CGCCGCGCGT CTGATTTGTT TTGTTGTTCT TCTGTTCTTC GTTAGTTTTC 
129X1/Sv strain mouse  CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAACCG CGCCGCGCGT CTGATTTGTT TTGTTGTTCT TCTGTTCTTC GTTAGTTTTC 
Korea 12 clone 1    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAACCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
Korea 35 clone 5    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAACCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
Korea 35 clone 15    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAGCCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
Korea 15 clone 1    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAACCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
UK 244 clone 1    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAACCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
Thailand 1 clone_1    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAGCCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
Thailand 2 clone 1    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAGCCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
Korea 16 clone_1    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAGCCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
Korea 16 clone 2    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAGCCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
Thailand 2 clone 3    CACTTCCCGC CCCCGTCTGA ATTTTTGCTT TCGGTTTTAC GCCGAAACCG CGCCGCGCGT CT-------- ---------- ---------- ---------- 
XMRV-R-I                                                                 *                 GATTTGT TTTGTTGTTC TTCT
I
Figure 2 Sequence alignment of XMRV LTR from 7 prostate cancer patients. The gag leader primer set XMRV-R-I/XMRV-F-O bind either side
of the XMRV specific deletion. Sequences were aligned against VP62 [Genbank:EF185282], MLV-releated virus CFS isolate CSF-type1 ([Genbank:
HM630562], as described in Lo [17]) and mouse strain 129X1/SvJ [Genbank AAHY01591888.1]. The alignment was conducted with clustalW using
BioEdit v7.0.5.3. Binding sites of primers XRMV-R-I and XMRV-F-O are shown. The asterisk shows the location of the A > G mutation.
Table 1 Frequency of positive PCR reactions using XMRV
LTR primers, mtDNA primers and IAP primers.
XMRV + XMRV -
IAP +
mtDNA +
21
(1
†)
94
(20)
IAP -
mtDNA -
0
(5)
322
(394*)
292 UK, 139 Korean, and 6 Thai samples were tested for XMRV, IAP and
mtDNA sequences by PCR.
†13 not done, *4 not done due to lack of sample.
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that the samples in question are infected with XMRV
and simultaneously contaminated by mouse DNA,
although this is unlikely since we found no IAP-negative
samples from which we amplified MLV-specific
sequences (data not shown). Also, the failure to detect
XMRV sequences other than in association with mouse
DNA contamination in our cohort does not mean that
the virus is not present in other, unrelated, cohorts.
It is difficult to explain how the contamination may
have occurred, especially since the samples came from
three unrelated centres in the UK, Korea and Thailand.
As both our negative tissue and PBS controls treated in
parallel with the FFPE were XMRV PCR-negative, it is
unlikely that contamination was introduced via reagents.
The UK FFPE tissue samples were stored boxed and
stacked in a cupboard in the histopathology department
for several years; and it is possible that contamination
happened during that time, although why only a few
s a m p l e s( 4 . 8 % )w e r eX M R Vp o s i t i v ea n dt h er e m a i n d e r
not is difficult to explain. Nor does it explain the Thai
and Korean results on tissue collected prospectively for
the study. It does, however, demonstrate the necessity of
controlling by highly specific and sensitive means for
mouse contamination.
Additional material
Additional file 1: Supplementary Methods. Materials and Methods.
Additional file 2: Figure S1. Sensitivity of mitochondria and IAP PCRs.
Additional file 3: Figure S2. Sequence alignment of IAP PCR products.
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